AIMS/HYPOTHESIS: Poly(ADP-ribose) polymerase activation depletes NAD+ and high-energy phosphates, activates protein kinase C, and affects gene expression in various tissues. This study was designed to characterise the effects of the potent, orally active poly(ADP-ribose) polymerase inhibitor PJ34 in the Wistar rat model of early diabetic neuropathy. METHODS: Control and streptozotocin-diabetic rats were maintained with or without PJ34 treatment (30 mg x kg(-1) x day(-1)) for two weeks, after two weeks without treatment. Endoneurial blood flow was assessed by hydrogen clearance; metabolites and high-energy phosphates were assayed by enzymatic spectrofluorometric methods; and poly(ADP-ribose) was detected by immunohistochemistry. RESULTS: Blood glucose concentrations were increased to a similar extent in untreated and PJ34-treated diabetic rats compared with controls. Intense poly(ADP-ribose) immunostaining was observed in the sciatic nerve of diabetic rats, but not in other groups. Final sciatic motor nerve conduction velocity and digital sensory nerve conduction velocity were reduced by 24% and 22% respectively in diabetic rats compared with controls (p<0.01 for both), and both were 98% corrected by PJ34 (p<0.01 vs diabetic group for both). In contrast, with PJ34 treatment, nerve blood flow showed a modest (17%) increase, and vascular conductance showed a tendency to increase. Free mitochondrial and cytosolic NAD+:NADH ratios, assessed from the glutamate and lactate dehydrogenase systems, phosphocreatine concentrations, and phosphocreatine:creatine ratios were decreased in diabetic rats and essentially normalised by PJ34. In both untreated and PJ34-treated diabetic rats, nerve glucose, sorbitol and fructose were increased to a similar extent. PJ34 did not affect any variables in control rats. CONCLUSIONS/ INTERPRETATION: Short-term poly(ADP-ribose) polymerase inhibitor treatment reverses functional and metabolic abnormalities of early diabetic neuropathy. Complete normalisation of nerve blood flow is not required for correction of motor or sensory nerve conduction velocities, provided that a therapeutic agent can restore nerve energy state via direct action on Schwann cells.
AIMS/HYPOTHESIS: Poly(ADP-ribose) polymerase activation depletes NAD+ and high-energy phosphates, activates protein kinase C, and affects gene expression in various tissues. This study was designed to characterise the effects of the potent, orally active poly(ADP-ribose) polymerase inhibitor PJ34 in the Wistar rat model of early diabetic neuropathy. METHODS: Control and streptozotocin-diabeticrats were maintained with or without PJ34 treatment (30 mg x kg(-1) x day(-1)) for two weeks, after two weeks without treatment. Endoneurial blood flow was assessed by hydrogen clearance; metabolites and high-energy phosphates were assayed by enzymatic spectrofluorometric methods; and poly(ADP-ribose) was detected by immunohistochemistry. RESULTS:Blood glucose concentrations were increased to a similar extent in untreated and PJ34-treated diabeticrats compared with controls. Intense poly(ADP-ribose) immunostaining was observed in the sciatic nerve of diabeticrats, but not in other groups. Final sciatic motor nerve conduction velocity and digital sensory nerve conduction velocity were reduced by 24% and 22% respectively in diabeticrats compared with controls (p<0.01 for both), and both were 98% corrected by PJ34 (p<0.01 vs diabetic group for both). In contrast, with PJ34 treatment, nerve blood flow showed a modest (17%) increase, and vascular conductance showed a tendency to increase. Free mitochondrial and cytosolic NAD+:NADH ratios, assessed from the glutamate and lactate dehydrogenase systems, phosphocreatine concentrations, and phosphocreatine:creatine ratios were decreased in diabeticrats and essentially normalised by PJ34. In both untreated and PJ34-treated diabeticrats, nerve glucose, sorbitol and fructose were increased to a similar extent. PJ34 did not affect any variables in control rats. CONCLUSIONS/ INTERPRETATION: Short-term poly(ADP-ribose) polymerase inhibitor treatment reverses functional and metabolic abnormalities of early diabetic neuropathy. Complete normalisation of nerve blood flow is not required for correction of motor or sensory nerve conduction velocities, provided that a therapeutic agent can restore nerve energy state via direct action on Schwann cells.
Authors: Csaba Szabó; Jon G Mabley; Suzanne M Moeller; Roman Shimanovich; Pál Pacher; László Virag; Francisco G Soriano; John H Van Duzer; William Williams; Andrew L Salzman; John T Groves Journal: Mol Med Date: 2002-10 Impact factor: 6.354
Authors: L Virág; P Jagtap; E Szabó; J G Mabley; L Liaudet; A Marton; D G Hoyt; K G Murthy; A L Salzman; G J Southan; C Szabó Journal: Nat Med Date: 2001-01 Impact factor: 53.440
Authors: Pal Pacher; Lucas Liaudet; Francisco Garcia Soriano; Jon G Mabley; Eva Szabó; Csaba Szabó Journal: Diabetes Date: 2002-02 Impact factor: 9.461
Authors: Robert D Hoeldtke; Kimberly D Bryner; Daniel R McNeill; Gerald R Hobbs; Jack E Riggs; Sarah S Warehime; Ian Christie; Gary Ganser; Knox Van Dyke Journal: Diabetes Date: 2002-09 Impact factor: 9.461
Authors: Irina G Obrosova; Fei Li; Omorodola I Abatan; Mark A Forsell; Katalin Komjáti; Pal Pacher; Csaba Szabó; Martin J Stevens Journal: Diabetes Date: 2004-03 Impact factor: 9.461
Authors: Irina G Obrosova; Pal Pacher; Csaba Szabó; Zsuzsanna Zsengeller; Hiroko Hirooka; Martin J Stevens; Mark A Yorek Journal: Diabetes Date: 2005-01 Impact factor: 9.461
Authors: Viktor R Drel; Sergey Lupachyk; Hanna Shevalye; Igor Vareniuk; Weizheng Xu; Jie Zhang; Nicholas A Delamere; Mohammad Shahidullah; Barbara Slusher; Irina G Obrosova Journal: Endocrinology Date: 2010-03-31 Impact factor: 4.736
Authors: Irina G Obrosova; Viktor R Drel; Pal Pacher; Olga Ilnytska; Zhong Q Wang; Martin J Stevens; Mark A Yorek Journal: Diabetes Date: 2005-12 Impact factor: 9.461
Authors: Olga Ilnytska; Valeriy V Lyzogubov; Martin J Stevens; Viktor R Drel; Nazar Mashtalir; Pal Pacher; Mark A Yorek; Irina G Obrosova Journal: Diabetes Date: 2006-06 Impact factor: 9.461
Authors: Subir K Roy Chowdhury; Elena Zherebitskaya; Darrell R Smith; Eli Akude; Sharmila Chattopadhyay; Corinne G Jolivalt; Nigel A Calcutt; Paul Fernyhough Journal: Diabetes Date: 2010-01-26 Impact factor: 9.461